- Home
- CYBN vs LRMR Comparison
CYBN vs LRMR Comparison
Compare CYBN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- LRMR
- Stock Information
- Founded
- CYBN 2019
- LRMR N/A
- Country
- CYBN Canada
- LRMR United States
- Employees
- CYBN N/A
- LRMR N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- LRMR Health Care
- Exchange
- CYBN Nasdaq
- LRMR Nasdaq
- Market Cap
- CYBN 153.7M
- LRMR 183.8M
- IPO Year
- CYBN N/A
- LRMR N/A
- Fundamental
- Price
- CYBN $5.91
- LRMR $2.00
- Analyst Decision
- CYBN Strong Buy
- LRMR Strong Buy
- Analyst Count
- CYBN 4
- LRMR 10
- Target Price
- CYBN $86.00
- LRMR $19.60
- AVG Volume (30 Days)
- CYBN 156.6K
- LRMR 906.5K
- Earning Date
- CYBN 02-11-2025
- LRMR 05-08-2025
- Dividend Yield
- CYBN N/A
- LRMR N/A
- EPS Growth
- CYBN N/A
- LRMR N/A
- EPS
- CYBN N/A
- LRMR N/A
- Revenue
- CYBN N/A
- LRMR N/A
- Revenue This Year
- CYBN N/A
- LRMR N/A
- Revenue Next Year
- CYBN N/A
- LRMR N/A
- P/E Ratio
- CYBN N/A
- LRMR N/A
- Revenue Growth
- CYBN N/A
- LRMR N/A
- 52 Week Low
- CYBN $5.81
- LRMR $1.96
- 52 Week High
- CYBN $17.86
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- CYBN 21.10
- LRMR 29.98
- Support Level
- CYBN $7.16
- LRMR $2.19
- Resistance Level
- CYBN $7.09
- LRMR $2.44
- Average True Range (ATR)
- CYBN 0.35
- LRMR 0.18
- MACD
- CYBN -0.07
- LRMR -0.01
- Stochastic Oscillator
- CYBN 5.03
- LRMR 4.81
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.